Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal imaging in neovascular AMD: Fovista (pegpleranib) plus anti-VEGF Phase 2a study
2015-000519-42Phase 2Terminated
- Sponsor
- IVERIC bio
- Start
- Aug 2015
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegpleranib in exudative macular degeneration, subfoveal choroidal neovascularization (CNV) and age-related macular degeneration (AMD) (3 arms), sponsored by IVERIC bio. Primary endpoint: Biomarker imaging endpoints. Started Aug 2015; status: terminated.
02
Drugs
pegpleranib
03
Conditions
exudative macular degenerationsubfoveal choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2015-000519-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000519-42.